A randomized trial of three polyethylene glycol regimens found that more patients tolerated and were willing to repeat low-volume same-day or split-dose prep compared to high-volume split-dose regimens.
Clarithromycin triple therapy should be used for first-line treatment of Helicobacter pylori infection only in patients with no history of macrolide exposure who live in areas where H. pylori resistance to clarithromycin is known to be low, among
Three propensity-matched cohorts of patients with nonvalvular atrial fibrillation who had incident exposure to dabigatran, rivaroxaban, or apixaban were compared.
Additionally, our results highlight the potential clinical utility of echocardiography for assessing NAFLD-related HF risk.
Oral sulfasalazine, diazo-bonded 5-aminosalicylates (5-ASAs), mesalazine, controlled ileal-release budesonide, and budesonide multimatrix, alone or in combination with rectal 5-ASA therapy, were assessed for comparative efficacy and tolerability.
Welcome to the first issue of ACP Gastroenterology Monthly, a new free monthly e-newsletter from the American College of Physicians, designed to inform primary care physicians of the current literature in gastroenterology/hepatology.
There was no significant difference in upper GI events between a pantoprazole group and a placebo group, although pantoprazole was associated with significantly reduced bleeding of gastroduodenal lesions, an industry-funded study found.
A randomized trial found that median length of hospital stay was 40.0 hours in the antibiotic group and 45.8 hours in the placebo group, with no significant between-group differences in adverse events or readmissions.
Endoscopic eradication therapy plus reflux control associated with decreased Barrett's recurrence rates
Standard reflux management protocol involved initial consultation that emphasized reflux control and proton-pump inhibitor (PPI) adherence, initiation or continuation of PPI therapy as described, medication reconciliation and assessment or
An editorial said the results highlight the importance of alternative biologic treatments and regimens for some patients but noted that further research is needed on cost-effectiveness.